Translate

Wednesday, July 2, 2014

  XARTEMIS™ XR
Dosed q12h, XARTEMIS™ XR may be taken less frequently than Percocet® dosed q4-6h.
  • Provides a total daily dose of oxycodone (30 mg) equivalent to one 5 mg tablet of Percocet® dosed every 4 hours (6 times daily).1,5
  • Twice-daily dosing means patients may not have to wake in the night to dose.
    • On the first day of treatment, the second dose may be taken at 8 hours after initial dose if pain intensity requires it.1
  • XARTEMIS XR may be taken with or without food.1
Tablets shown are not actual size.
IMPORTANT RISK INFORMATION
XARTEMIS XR tablets should be swallowed whole one at a time. Do not break, chew, crush, cut, dissolve or split the tablets. Swallow with enough water to ensure complete swallowing immediately after placing in mouth.
Release Date: April 8, 2014
Expiration Date: April 8, 2015

Co-Chairs

  • Timothy R. Deer, MD

    President and Chief Executive Officer
    Center for Pain Relief
    Charleston, West Virginia
  • Richard L. Rauck, MD

    Clinical Associate Professor
    Department of Anesthesiology
    Wake Forest University School of Medicine
    Winston-Salem, North Carolina

Goal

The goal of this program is to educate clinicians about the current landscape in intrathecal (IT) therapy in the treatment of severe chronic pain and to provide useful information on referring patients for this therapy or using this therapy.

Learning Objectives

At the completion of this activity, participants should be better able to:
  1. Describe the advantages of delivering medication to the site of action.
  2. Identify patients who are most likely to benefit from IT therapy and ways to find health care professionals who provide IT therapy.
  3. Discuss the IT medications currently on the market, including trialing, dose titration, and maintenance using ziconotide therapy with implanted pumps.
  4. Review the tolerability and safety of IT therapy, including management of adverse events for both IT ziconotide and IT morphine.

Intended Audience

Physicians who treat pain, including anesthesiologists and pain specialists.

Statement of Need

Education on the appropriate use of IT therapy for chronic pain is necessary based on the following practice gaps, which were identified via needs assessment, including a comprehensive literature review:
  • Clinicians may not be familiar with relatively recent studies on the usefulness of IT therapy.
  • There is a relative paucity of literature to guide clinicians with respect to patient selection and referrals to other clinicians who can provide IT therapy.
  • Because a number of medications are used in IT therapy, but only 2 are FDA-approved for this use, clinicians need education on availability and proper use.
  • Clinicians may not be aware of the tolerability and safety profiles of IT medications, and how to manage adverse events.

Estimated Time for Completion

1 hour

Course Format

Monograph

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group and Applied Clinical Education. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

To receive CME credit, participants should read the preamble, read the monograph, and visit www.cmezone.com/intrathecal to complete the online post-test and activity evaluation. CME certificates will be made available immediately upon successful completion.

Fees

There are no fees for participating in or receiving credit for this activity.

Disclosure of Conflicts of Interest

Global Education Group requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are vetted thoroughly by Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
  • Timothy R. Deer, MD: Flowonix, Jazz Pharmaceuticals, Medtronic (consultant/independent contractor); Medtronic (grant/research support); Jazz Pharmaceuticals (speakers' bureau)
  • Richard L. Rauck, MD: Jazz Pharmaceuticals, Mallinckrodt, Medtronic (consultant/independent contractor; grant/research support); Jazz Pharmaceuticals (honoraria, speakers' bureau)
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:
  • George Ochoa: Nothing to disclose
  • Jennifer Kulpa: Nothing to disclose
  • A shley Marostica, RN , MSN : Nothing to disclose
  • A manda Glazer, PhD: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Applied Clinical Education do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or courses of diagnosis or treatment discussed should not be used by clinicians without evaluation of patient conditions, contraindications, applicable manufacturer’s product information, and the recommendations of other authorities.

Accreditor Contact Information

For information about the accreditation of this program, please contact Global Education Group at (303) 395-1782 or inquire@globaleducationgroup.com.

System Requirements

PC
  • Microsoft Windows 2000 SE or greater
  • Flash Player Plugin (v7.0.1.9 or greater)
  • Internet Explorer (v5.5 or greater) or Firefox Adobe Acrobat Reader
MAC
  • MAC OS 10.2.8 Flash Player Plugin (v7.0.1.9 or greater)
  • Safari Adobe Acrobat Reader
  • Internet Explorer is not supported on the Macintosh

Le dépistage du cancer du sein est-il encore utile ?

L’efficacité du dépistage du cancer du sein par mammographie systématique donne matière régulièrement à des publications, parfois contradictoires. Outre les discussions méthodologiques, la prise en compte des effets indésirables et des surdiagnostics, il est une variable dont il faut tenir compte, ce sont les progrès récents réalisés dans les stratégies thérapeutiques. La chimiothérapie et les traitements néo-adjuvants ont en quelques années amélioré la survie des patientes atteintes de cancer du sein, amenant certains observateurs à poser la question de savoir si le dépistage précoce reste encore vraiment utile.
Une équipe norvégienne a analysé la mortalité liée au cancer du sein en distinguant les cancers diagnostiqués avant et après la première invitation au dépistage systématique. Ont été analysées les données de toutes les norvégiennes âgées de 50 à 79 ans entre 1986 et 2009, soit plus de 15 millions personnes-années. Le dépistage a été mis en place en 1995 et étendu progressivement jusqu’en 2005 sur tout le territoire. Dans leur évaluation, les auteurs ont pris en compte les effets des modifications des stratégies thérapeutiques au fil du temps, en ajustant les résultats pour les tendances observées dans les variations de la mortalité par cancer du sein dans le pays au fil du temps.
Après ajustement pour l’âge, l’année de naissance, la région de résidence et la tendance nationale des décès par cancer du sein, l’invitation au dépistage est associée à une réduction de 28 % du risque de mortalité par cancer du sein (risque relatif [RR] 0,72 ; intervalle de confiance à 95 % [IC] 0,64 à 0,79). L’âge de 70 ans marque la sortie du dépistage organisé, mais le bénéfice du dépistage persiste encore quelques années, et 5 à 10 après la sortie, le risque de mortalité par cancer du sein est encore inférieur de 21 % dans le groupe qui avait été dépisté.
L’attention plus importante que les femmes portent au cancer du sein ainsi que les progrès thérapeutiques ont permis d’en réduire la mortalité. L’on peut alors s’attendre à une réduction du bénéfice absolu du dépistage. Il est confirmé dans cette étude, puisque les auteurs estiment qu’il est désormais nécessaire d’inviter au dépistage 368 femmes pour éviter 1 décès par cancer du sein. En 1980, l’EuroscreenWorking Group estimait entre 111 et 143 le nombre de femmes à dépister pour éviter 1 décès par cancer du sein.
Ces résultats ne manquent pas d’intérêt et seront à porter au dossier pour l’évaluation de l’intérêt du dépistage. Mais cette étude ne prétend pas affirmer cet intérêt. Manque en effet l’évaluation des risques tels que faux positifs, risques des surdiagnostics et des surtraitements. Juger de l’intérêt d’un dépistage nécessite d’évaluer précisément sa balance bénéfice-risque.
Dr Roseline Péluchon
Références
Weedon-Fekjær W. et coll. : Modern mammography screening and breast cancer mortality: population study. BMJ 2014; 348: g3701. doi: 10.1136/bmj.g3701.

Tuesday, July 1, 2014

The consequences of chronic pain.

J Pain Palliat Care Pharmacother. 2012;26(1):64-7.

Abstract

Questions from patients about analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. The topic addressed in this issue is untreated/undertreated chronic pain and the physical, emotional, and social consequences that can profoundly affect a patient's quality of life. Chronic pain is no longer considered a symptom; it is a disease entity itself. Anxiety and depression often coexist with chronic pain. Chronic pain is the enemy of happiness. Further, chronic pain can activate the sympathetic nervous system, leading to the fight-or-flight response.

Ziconotide.

J Pain Palliat Care Pharmacother. 2014 Mar;28(1):73-4.


Abstract

Questions from patients about pain conditions and analgesic pharmacotherapy and responses from authors are presented to help educate patients and make them more effective self-advocates. 
The topics addressed in this issue are ziconotide, a novel approach to pain management that is derived from a snail toxin, its uses and possible side effects.